27,480 Shares in Pfizer Inc. (NYSE:PFE) Acquired by Oxford Asset Management LLP

Oxford Asset Management LLP acquired a new position in shares of Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 27,480 shares of the biopharmaceutical company’s stock, valued at approximately $729,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Retirement Wealth Solutions LLC purchased a new position in Pfizer in the fourth quarter valued at $26,000. Rialto Wealth Management LLC purchased a new position in Pfizer in the fourth quarter valued at approximately $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer during the fourth quarter worth approximately $28,000. Noble Wealth Management PBC purchased a new stake in shares of Pfizer during the 4th quarter worth approximately $31,000. Finally, Curio Wealth LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $32,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on PFE shares. Cantor Fitzgerald started coverage on Pfizer in a report on Tuesday. They set a “neutral” rating and a $24.00 price target for the company. UBS Group lowered their target price on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a report on Tuesday, April 8th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $29.57.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock bought 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.06% of the stock is currently owned by company insiders.

Pfizer Trading Up 0.7 %

Pfizer stock opened at $22.95 on Friday. The stock has a market cap of $130.16 billion, a PE ratio of 16.28, a P/E/G ratio of 0.64 and a beta of 0.67. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a 50-day moving average price of $24.58 and a 200 day moving average price of $25.97. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.10 earnings per share. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be paid a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.49%. Pfizer’s payout ratio is currently 121.99%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.